Interim Report 2026
Filed with HKEX · Stock code 2563 · · 75 pages · English
Summary by 6ix AI
The report highlights significant advancements in the company's R&D pipeline, particularly regarding its core product, Utidelone Injection, and its various clinical trials. Financial highlights indicate a substantial increase in revenue and a reduction in net loss compared to the previous year. The report also discusses the company's strategic marketing efforts and the progress of multiple clinical trials for cancer treatments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Beijing Biostar Pharmaceuticals Co., Ltd. on 6ix
Earlier from Beijing Biostar Pharmaceuticals
- Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
- The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
- Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
Later from Beijing Biostar Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement - UTD2 of biostar achieves first patient dosing in phase III clinical study for HER2-negative advanced breast cancer
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
- Change of secretary to the board and joint company secretary
Follow Beijing Biostar Pharmaceuticals into a list and get an email when it puts out news.
Follow Beijing Biostar Pharmaceuticals